Flutter Entertainment 2Q Revenue Surges on Continued U.S. Sports Betting Momentum
By Denny Jacob
Flutter Entertainment said revenue surged 20% in its latest quarter, indicating sports betting in the United States continues to have a long runway.
The parent company of FanDuel and other gaming and gambling brands logged net income of $297 million, or $1.45 a share, for the second quarter ended June 30, up from $64 million, or 37 cents a share, a year earlier. Adjusted earnings were $2.61 a share.
Revenue rose to $3.61 billion from about $3 billion last year.
Chief Executive Peter Jackson said improvements to its products drove the proportion of live betting handle to be more than 400 basis points higher than last year during the National Basketball Association's playoff period, as well as increasing its parlay penetration in Major League Baseball.
Flutter raised its outlook for the year, citing its quarterly performance, the benefit of positive sports results and momentum into the current quarter. It now expects U.S. revenue to come in between $6.05 billion and $6.35 billion in 2024, up from its prior guidance for revenue of $5.8 billion to $6.2 billion.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
August 13, 2024 17:10 ET (21:10 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks